Cystoid macular oedema following cataract surgery: A review

2019 ◽  
Vol 47 (3) ◽  
pp. 346-356 ◽  
Author(s):  
Jina V. Han ◽  
Dipika V. Patel ◽  
David Squirrell ◽  
Charles NJ. McGhee
Keyword(s):  
Cataract Surgery ◽  
Macular Oedema ◽  
Cystoid Macular Oedema

Bilateral fingolimod-associated macular oedema development after cataract surgery

2021 ◽  
Vol 14 (6) ◽  
pp. e240562
Author(s):  
Matthew Gillam ◽  
Theresa Richardson
Keyword(s):  
Multiple Sclerosis ◽  
Cataract Surgery ◽  
Macular Oedema ◽  
Topical Therapy ◽  
Cystoid Macular Oedema ◽  
Topical Steroids ◽  
Visual Recovery ◽  
Anti Inflammatory

Postoperative cystoid macular oedema (CMO) is a recognised complication of cataract surgery, occurring in around 1.5% of cases. It is generally managed with topical steroids or non-steroidal anti-inflammatory medications. We present a case of a patient who developed bilateral sequential CMO following bilateral sequential cataract surgery which was non-responsive to topical therapy and worsened following sub-Tenons administration of steroid. The patient took fingolimod for multiple sclerosis both prior to and during the period of cataract surgery which is known to result in the development of macular oedema in some patients. On fingolimod cessation, the oedema resolved over a period of 5 months with good visual recovery. We present this case to inform cataract surgeons of the risk of fingolimod-associated macular oedema in patients undergoing cataract surgery and to inform neurologists of the potential need to adjust treatment for patients undergoing cataract surgery.

Pathogenesis of Pseudophakic Cystoid Macular Oedema

2012 ◽  
Vol 06 (05) ◽  
pp. 290
Author(s):  
Conceição Lobo ◽  
Keyword(s):  
Optical Coherence Tomography ◽  
Cataract Surgery ◽  
Inflammatory Mediators ◽  
Diagnostic Tool ◽  
Macular Oedema ◽  
Cystoid Macular Oedema ◽  
Blood Retinal Barrier ◽  
Non Invasive ◽  
Operative Complications ◽  
Inflammatory Drugs

Cystoid macular oedema (CMO) is a primary cause of reduced vision after cataract surgery even after uneventful surgery. The incidence of clinical CMO following modern cataract surgery is 1.0-2.0 % but the high number of surgeries performed worldwide makes this entity an important problem. Pre-existing conditions such as diabetes and intra-operative complications increase the risk of developing CMO post-operatively. CMO is caused by an accumulation of intra-retinal fluid in the outer plexiform and inner nuclear layers of the retina, as a result of the breakdown of the blood-retinal barrier. The mechanisms that lead to this condition are not completely understood. However, the principal hypothesis is that the surgical procedure is responsible for the release of inflammatory mediators, such as prostaglandins. Optical coherence tomography is at present an extremely useful non-invasive diagnostic tool. Guidelines for the management CMO should be focused essentially on prevention and are based on the principal pathogenetic mechanisms, including the use of anti-inflammatory drugs.

Aqueous flare is increased in patients with clinically significant cystoid macular oedema after cataract surgery

2013 ◽  
Vol 97 (7) ◽  
pp. 862-865 ◽  
Author(s):  
Lebriz Ersoy ◽  
Albert Caramoy ◽  
Tina Ristau ◽  
Bernd Kirchhof ◽  
Sascha Fauser
Keyword(s):  
Cataract Surgery ◽  
Macular Oedema ◽  
Cystoid Macular Oedema ◽  
Aqueous Flare ◽  
Clinically Significant
Sign in / Sign up

Export Citation Format

Share Document